• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Report: Boston Scientific pauses Lotus Edge heart valve in Europe

Report: Boston Scientific pauses Lotus Edge heart valve in Europe

October 31, 2016 By Brad Perriello

Boston Scientific's Lotus Edge

Boston Scientific (NYSE:BSX) is reportedly pausing implantations of its next-generation Lotus Edge replacement heart valve in Europe to investigate a locking mechanism issue.

Marlborough, Mass.-based Boston Scientific has implanted about 200 of the Lotus Edge transcatheter aortic valve replacements in Europe, according to Barclays analyst Matthew Taylor, encountering about a 4% rate of “some issues with [the] locking mechanism of the valve.”

“In these cases (incidence rate of ~4%), the device was recaptured and a new valve was implanted with no major adverse events,” Taylor wrote today in a note to investors.

The company pulled Lotus Edge from the market in Europe, where it won CE Mark approval last month, so it can figure out the problem.

“Boston Scientific is initiating a voluntary removal of field inventory of the Lotus Edge valve system. During the initial launch to a limited number of European sites, we received reports that in some cases the device could not be fully locked and therefore the procedure could not be completed. In all cases, patients were successfully treated with a new valve,” the company told MassDevice.com in an emailed statement. “This action does not impact patients who have already been implanted with the device. The company is completing an evaluation to identify the root cause of the issue. Physicians are advised to use the previous generation Lotus valve system, which continues to be available in Europe.”

“BSX does not think that correcting Edge will require a valve redesign, but having made this decision [Oct. 28], cannot answer the question as to when it will be back in the market with precision. It does not anticipate that this will change any timelines or financial guidance including the Reprise trials or launch of Lotus in the U.S,” Taylor wrote.

Yesterday at the annual Transcatheter Cardiovascular Therapies conference in Washington, D.C., Dr. Ian Meredith (who’s slated to replace chief medical officer Dr. Keith Dawkins next year) presented feasibility data on 21 patients treated with the Lotus Edge device, showing 100% technical success, no or only trace paravalvular leakage and a 4.8% stroke rate, a 9.5% rate of new pacemaker implantation and no repeat procedures.

“The company believes it has something very differentiated; it would not comment on pricing strategy but said that looking at major medtech markets where there are three 3 share players that split the market is illustrative. It would be disappointed with 5% to 10% share given the talent and investment that it is putting in the market and expects to be a leader in the [TAVR] space,” Taylor wrote. “Dr. Dawkins noted increased confidence that BSX can be competitive with 2nd-generation valves on pacer rates, driven by changes in technique and technology. Further, BSX outlined plans for its intermediate- and low-risk trials (Reprise IV and V) which will start in 2017; Reprise IV will randomize versus EW’s S3 and Reprise V will go against surgery.”

Filed Under: Cardiovascular, Clinical Trials, Replacement Heart Valves Tagged With: Boston Scientific, TCT 2016, Transcatheter Cardiovascular Therapeutics symposium (TCT)

In case you missed it

  • Abbott imaging catheter recall flagged as Class I by FDA
  • Will Johnson & Johnson buy Boston Scientific?
  • Needham & Co. downgrades Medtronic, Zimmer Biomet shares
  • DoMore Diagnostics wins CE mark for AI algorithm that predicts colorectal cancer outcomes
  • Quidel, Ortho Clinical Diagnostics combine to form in vitro diagnostics company
  • Zimmer Biomet adds ESG and CEO visibility to executive’s duties
  • U of Maryland scientist to set up NIH’s new Advanced Research Projects Agency for Health
  • ‘Catastrophic explosion’ and resin shortage led Medtronic’s supply chain problems
  • FDA grants IDE for MedAlliance’s sirolimus-eluting balloon
  • Medtronic ‘hopeful’ on FDA clearance for next-gen diabetes tech in FY 2023
  • Bigfoot Biomedical adds former Insulet VP as chief commercial officer
  • Medtronic, DaVita to form new kidney care company
  • Medtronic stock down on Q4 earnings miss
  • 3M Health Care Business president is leaving this year
  • Device developer SeaStar Medical hires chief medical officer
  • AccuPulse raises $10M Series A
  • Exactech announces first U.S. surgeries with its nex-gen laser cage glenoid

RSS From Medical Design & Outsourcing

  • Download COMSOL News Special Edition Biomedical
    Get instant access to this special edition of COMSOL News where you will read user stories that showcases how simulation enables engineers, researchers, and scientists explore and analyze biomedical designs. Download Now.       The post Download COMSOL News Special Edition Biomedical appeared first on Medical Design and Outsourcing.
  • Qosina adds new tube-to-tube barb connectors
    Qosina has added 25 new tube-to-tube barb connectors to its portfolio, the OEM single-use component supplier for the medical and pharmaceutical industries said this week. Ronkonkoma, New York-based Qosina said its inventory of tube-to-tube barb connectors is available in more than 500 configurations. The connectors can fit inner tube diameters between 1/32 in and 1… […]
  • Abbott imaging catheter recall flagged as Class I by FDA
    The FDA has identified the Abbott (NYSE:ABT) recall of its Dragonfly OpStar Imaging Catheter as a Class I recall. That’s the most serious level of a medical device recall, carrying the risk of serious injury or death. Five incidents, one injury and zero deaths were reported when Abbott initiated the recall on April 11. The… […]
  • Zimmer Biomet adds ESG and CEO visibility to executive’s duties
    Zimmer Biomet (NYSE:ZBH) today announced additional responsibilities for Investor Relations SVP and Chief Communications Officer Keri Mattox. Mattox’s new title at the Warsaw, Indiana-based orthopedics company is chief communications and administration officer. She will be responsible for “building and executing a comprehensive strategy around Environmental, Social and Governance (ESG) initiatives and increasing CEO visibility, engagement… […]
  • ‘Catastrophic explosion’ and resin shortage led Medtronic’s supply chain problems
    Medtronic CEO Geoff Martha today said a “catastrophic explosion” in Medtronic’s supply chain for packaging and a shortage of resins were the biggest issues hurting the company’s fourth-quarter performance. Fridley, Minnesota-based Medtronic (NYSE:MDT) reported about $350 million less in sales than analysts were expecting for the quarter, which ended April 29. Martha said about 75%… […]
  • 3M Health Care Business president is leaving this year
    3M Health Care Business Group President Mojdeh Poul will retire from the company on July 1, 2022. Poul joined Maplewood, Minnesota-based 3M (NYSE:MMM) in 2011 as the global business VP of critical and chronic care solutions. She later became VP and general manager of the company’s food safety business and president of numerous 3M divisions,… […]
  • Iterative Scopes announces positive data in Skout AI colonoscopy algorithm clinical trial
    Iterative Scopes this week announced positive trial data in a study of its colorectal cancer screening algorithm, Skout. Cambridge, Massachusetts-based Iterative Scopes designed Skout as a computer-aided device (CADe) that uses artificial intelligence and computer vision technology to detect suspicious tissue and provide real-time feedback for gastroenterologists performing the procedure. Get the full story on… […]
  • Device developer SeaStar Medical hires chief medical officer
    SeaStar Medical has hired Dr. Kevin Chung as chief medical officer of the medtech developer starting July 1. Denver-based SeaStar is developing a platform therapy focused on hyperinflammation of vital organs. The company’s Selective Cytopheretic Device was designated as a breakthrough device by the FDA earlier this year. SeaStar is set to go public in… […]
  • Varta presents microbattery product portfolio at Computex 2022
    Varta will present its broad product portfolio of microbatteries, which make a wide range of future-proof applications possible, at Computex in Taipei starting today. Varta’s microbattery product portfolio ranges from rechargeable lithium-ion button cells to nickel metal hydride button cells, primary silver oxide cells, primary lithium button cells and cylindrical lithium batteries to hydrogen gas… […]
  • Entegris opens Life Sciences Technology Center in Massachusetts
    Entegris (Nasdaq:ENTG) announced today that it opened a new Life Sciences Technology Center in Billerica, Massachusetts. The new Life Sciences Technology Center was built to offer life sciences customers the opportunity to leverage Entegris’ cold-chain supply expertise to optimize processes, reduce costs and increase speed to market. Get the full story at our sister site,… […]
  • MedAcuity hires SVP of business development
    Medtech software development firm MedAcuity today said it has hired Simon Johnson as SVP of business development. Westford, Massachusetts-based MedAcuity said Johnson previously built the client partner team and managed strategic clients at digital consultancy Mobiquity. He also served as SVP of client services at GreenPages Technologies, responsible for driving services revenue growth leading to… […]

Primary Sidebar

DeviceTalks Weekly

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS